Vilazodone for Cannabis Dependence: A Randomized, Controlled Pilot Trial

American Journal on Addictions

Volumn 25, Issue 1, 2016, Pages 69-75

  McRae Clark, Aimee L ^a   Baker, Nathaniel L ^a   Gray, Kevin M ^a   Killeen, Therese ^a   Hartwell, Karen J ^a,b   Simonian, Susan J ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c Department of Teacher Education and Department of Sociology and Anthropology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; PLACEBO; VILAZODONE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CANNABIS ADDICTION; CANNABIS USE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE TREATMENT; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SELF REPORT; SEX DIFFERENCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINE LEVEL; YOUNG ADULT; ADOLESCENT; AGED; MARIJUANA ABUSE; MIDDLE AGED; MOTIVATIONAL INTERVIEWING; MULTIMODALITY CANCER THERAPY; SEXUAL DEVELOPMENT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; MOTIVATIONAL INTERVIEWING; PILOT PROJECTS; SEROTONIN UPTAKE INHIBITORS; SEX CHARACTERISTICS; TREATMENT OUTCOME; VILAZODONE HYDROCHLORIDE; YOUNG ADULT;

EID: 84957060400     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/ajad.12324     Document Type: Article

References (27)

1. McRae AL, Budney AJ, Brady KT. Treatment of marijuana dependence: A review of the literature. J Subst Abuse Treat. 2003;24:369-376
2. Nordstrom BR, Levin FR. Treatment of cannabis use disorders: A review of the literature. Am J Addict. 2007;16:331-342
3. Weinstein AM, Gorelick DA. Pharmacological treatment of cannabis dependence. Curr Pharm Des. 2011;17:1351-1358
4. Marshall K, Gowing L, Ali R, et al. Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev. 2014;12:CD008940
5. Gomes FV, Resstel LB, Guimaraes FS. The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology (Berl). 2011;213: 465-473
6. Hill MN, Sun JC, Tse MT, et al. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int J Neuropsychopharmacol. 2006;9:277-286
7. Mato S, Vidal R, Castro E, et al. Long-term fluoxetine treatment modulates cannabinoid type 1 receptor-mediated inhibition of adenylyl cyclase in the rat prefrontal cortex through 5-hydroxytryptamine 1A receptor-dependent mechanisms. Mol Pharmacol. 2010;77:424-434
8. Zanelati TV, Biojone C, Moreira FA, et al. Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors. Br J Pharmacol. 2010;159:122-128
9. McRae-Clark AL, Carter RE, Killeen TK, et al. A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend. 2009;105:132-138
10. McRae-Clark AL, Baker NL, Gray KM, et al. Buspirone treatment of cannabis dependence: A randomized, placebo-controlled trial. Drug Alcohol Depend. 2015;156:29-37
11. Cornelius JR, Salloum IM, Haskett RF, et al. Fluoxetine versus placebo for the marijuana use of depressed alcoholics. Addict Behav. 1999;24: 111-114
12. Cornelius JR, Bukstein OG, Douaihy AB, et al. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend. 2010;112:39-45
13. Weinstein AM, Miller H, Bluvstein I, et al. Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: A double-blind placebo-controlled study. Am J Drug Alcohol Abuse. 2014;40:16-22
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. (text rev) Washington, D.C: 2000
15. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/ P), New York: Biometrics Research, New York State Institute; 2002
16. Sobell LC, Sobell MB. Timeline follow-back: A technique for assessing self-reported ethanol consumption. In: J. Allen C, Litten RZ, eds. Measuring Alcohol Consumption: Psychological and Biological Methods, pp. 41-72; Totowa, NJ: Humana Press; 1992
17. Heishman SJ, Evans RJ, Singleton EG, et al. Reliability and validity of a short form of the Marijuana Craving Questionnaire. Drug Alcohol Depend. 2009;102:35-40
18. Hamilton M. The assessment of anxiety states by rating. Br J Psychiatry. 1959;32:50-55
19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-61
20. Steinberg KL, Roffman RA, Carroll KM, et al. Brief Counseling for Marijuana Dependence: A Manual for Treating Adults, (Vol. HHS Publication No. (SMA) 12-4211). Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration; 2005
21. Stout RL, Wirtz PW, Carbonari JP, et al. Ensuring balanced distribution of prognostic factors in treatment outcome research. J Stud Alcohol. 1994;70-75
22. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130
23. Carpenter KM, McDowell D, Brooks DJ, et al. A preliminary trial: Double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict. 2009;18:53-64
24. Levin FR, Mariani J, Brooks DJ, et al. A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction. 2013;108: 1084-1094
25. Cooper ZD, Haney M. Investigation of sex-dependent effects of cannabis in daily cannabis smokers. Drug Alcohol Depend. 2014;136:85-91
26. Copersino ML, Boyd SJ, Tashkin DP, et al. Sociodemographic characteristics of cannabis smokers and the experience of cannabis withdrawal. Am J Drug Alcohol Abuse. 2010;36:311-319
27. Eskridge KD, Guthrie SK. Clinical issues associated with urine testing of substances of abuse. Pharmacotherapy. 1997;17:497-510